Bortezomib and osteoclasts and osteoblasts

Michal T. Krauze, G. David Roodman

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Scopus citations

Abstract

Bortezomib is the first-in-class proteasome antagonist approved for treatment of myeloma. It is active in newly diagnosed, relapsed, and refractory patients and is now being used as a platform for combinations with other new agents for myeloma. In addition to its anti-myeloma effect, bortezomib also targets the bone microenvironment and can inhibit osteoclast formation and stimulate osteoblast activity in patients with myeloma. Potentially, combination of bortezomib with other agents that stimulate bone formation or block bone resorption will further enhance the anti-myeloma effects of bortezomib and overcome the contribution of the tumor microenvironment to myeloma growth. In this chapter, we discuss the potential mechanisms responsible for bortezomib's effects on osteoclast and osteoblast activity in myeloma.

Original languageEnglish (US)
Title of host publicationDrugs for HER-2-positive Breast Cancer
EditorsMichael Parnham, Jacques Bruinvels
Pages43-52
Number of pages10
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Publication series

NameMilestones in Drug Therapy

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Fingerprint Dive into the research topics of 'Bortezomib and osteoclasts and osteoblasts'. Together they form a unique fingerprint.

  • Cite this

    Krauze, M. T., & Roodman, G. D. (2010). Bortezomib and osteoclasts and osteoblasts. In M. Parnham, & J. Bruinvels (Eds.), Drugs for HER-2-positive Breast Cancer (pp. 43-52). (Milestones in Drug Therapy). https://doi.org/10.1007/978-3-7643-8948-2_3